It is apparent that patients failing on a rifampicin containing continuation phase in the first-line regimen cannot be cured with the recommended retreatment regimen: the only effect is the potential to also acquire ethambutol resistance.

Countries not disposing of second-line drugs and an infrastructure to deliver them would therefore preferably choose a continuation phase in the first-line regimen that is not based on rifampicin.

To top